← All trials
NCT01259934
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 1996
- Primary completion
- Jun 1, 2008
- Completion date
- Jun 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 855
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Karolinska InstituteLead sponsor
- MerckCollaborator
- University of CopenhagenOverall official - principal investigator
- University of GothenburgOverall official - principal investigator
- University of OsloOverall official - principal investigator
- University of Southern DenmarkOverall official - principal investigator
- University of HelsinkiOverall official - principal investigator
- Karolinska InstituteStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.